Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 'Polyclonal mixture of pathogenic antigens, toxins, and host immune components' refers to the broad array of inflammatory and infectious mediators present in the systemic circulation during severe illness, such as sepsis or systemic inflammatory response syndrome (SIRS) (Nierhaus et al., 2018, Critical Care). This heterogeneous target includes pathogen-associated molecular patterns (PAMPs) like bacterial endotoxins, damage-associated molecular patterns (DAMPs), and a variety of host-derived cytokines including Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-alpha) (Monard et al., 2023, J. Clin. Med.). Because these components drive the 'cytokine storm' and subsequent multi-organ failure, they are the focus of broad-spectrum therapeutic interventions (CytoSorbents Corp, 2023). Therapeutic approaches include extracorporeal blood purification devices like CytoSorb, which utilize polymer beads to adsorb these substances, and intravenous immunoglobulin (IVIG) preparations that provide polyclonal antibodies to neutralize toxins and antigens (Perez et al., 2017, J. Allergy Clin. Immunol.). The primary clinical objective in targeting this mixture is to reduce the overwhelming inflammatory burden and restore immunological balance in critically ill patients.
Extracorporeal adsorption of inflammatory mediators and toxins; Neutralization of antigens and toxins via polyclonal antibody binding.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polyclonal mixture of pathogenic antigens, toxins, and host immune components.